Preferential cyclooxygenase 2 inhibitors in postoperative pain treatment Review article

Article Sidebar

Requires Subscription PDF (Język Polski)


Published: Mar 31, 2015
Keywords:
COX-2 inhibitors, postoperative pain

Main Article Content

Hanna Misiołek
Katedra Anestezjologii, Intensywnej Terapii i Medycyny Ratunkowej, Wydział Lekarski z Oddziałem Lekarsko-Dentystycznym w Zabrzu, Śląski Uniwersytet Medyczny w Katowicach
Maja Copik
Katedra Anestezjologii, Intensywnej Terapii i Medycyny Ratunkowej, Wydział Lekarski z Oddziałem Lekarsko-Dentystycznym w Zabrzu, Śląski Uniwersytet Medyczny w Katowicach

Abstract

Accurate postoperative pain management is crucial for successful modern surgery. The most commonly used currently is the concept of multimodal analgesia which means combining different kinds of anaesthetic techniques with various groups of analgesic drugs. To make postoperative pain management more efficient guidelines are developed. One of the groups of drugs listed in current polish postoperative pain management guidelines are nonsteroidal anti-inflammatory drugs (NSAIDS) containing also preferential cyclooxygenase 2 inhibitors (COX-2) like nimesulide and meloxicam. Those drugs are available in different oral formulations and because of their way of action can be used in many specific groups of patients suffering from postoperative pain both in hospitals and in ambulatory surgery.

Article Details

How to Cite
Misiołek, H., & Copik, M. (2015). Preferential cyclooxygenase 2 inhibitors in postoperative pain treatment. Medycyna Faktow (J EBM), 8(1(26), 79-84. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2328
Issue
Vol 8 No 1(26) (2015)
Section
Articles

Copyright © by Medical Education. All rights reserved.

References

1. Misiołek H., Cettler M., Woroń J. et al.: The 2014 guidelines for post-operative pain management. Anaesth. Intens. Ther. 2014; 46: 221-244.
2. Rainsford K.D.: Nimesulide: actions and use Birkhaeuser Verlag. Basel-Boston-Berlin 2005.
3. Klimiuk A.P., Sierakowski S.: Zastosowanie nimesulidu w chorobach reumatycznych. Nowa Medycyna 2/2002.
4. Bianchi M., Broggini M.: Anti-hyperalgesic effects of nimesulide: studies in rats and humans. Int. J. Clin. Pract. supl. 2002; (128): 11-19.
5. Castellsague J., Pisa F., Rosole V. et al.: Risk of upper gastrointestinal complications in a cohort of users of nimesulide and other nonsteroidal antiinflammatory drugs in Friuli Venezia Giulia, Italy. Pharmacoepidemiol. Drug Saf. 2013; 22(4): 365-375.
6. Misiołek H., Copik M.: Meloksikam ODT: nowe podejście do starego problemu. Medycyna i Życie 2014; 3-4.
7. Asghar W., Jamali F.: The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review. Inflammopharmacology 2014; 17 [Epub ahead of print].
8. McGettigan P., Henry D.: Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011; 8(9).
9. Atkinson T.J., Fudin J., Jahn H.L. et al.: What’s new in NSAID pharmacotherapy: oral agents to injectables. Pain Med. 2013; 14(supl. 1): S11-7.
10. Villalba B.T., Ianiski F.R., Wilhelm E.A. et al.: Meloxicam-loaded nanocapsules have antinociceptive and antiedematogenic effects in acute models of nociception. Pain. Med. 2013; 14(supl. 1): S11-7.